Related Experiment Video
Updated: Jun 26, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Managing chronic coronary syndrome: how do we achieve optimal patient outcomes?
Antonis A Manolis1, Theodora A Manolis2, Antonis S Manolis3
1Department of Medicine, Elpis General Hospital, Athens, Greece.
Insights
Chronic coronary syndrome (CCS) is a major cause of death. This review covers CCS phenotypes, diagnostic methods like CCTA and CAC scoring, and multidisciplinary management including new therapies and cardiac rehabilitation.
Area of Science:
- Cardiology
- Cardiovascular Medicine
Background:
- Chronic coronary syndrome (CCS) is a leading global cause of mortality and high hospitalization rates.
- Understanding CCS phenotypes is crucial for effective patient management.
Purpose of the Study:
- To review current diagnostic modalities for CCS, including noninvasive and invasive testing.
- To discuss multidisciplinary management strategies and emerging therapeutic options for CCS.
- To highlight the role of cardiac rehabilitation and advanced treatments for refractory symptoms.
Main Methods:
- Literature search of medical databases for CCS and its management.
- Review of diagnostic techniques: stress-echocardiography, coronary computed-tomography angiography (CCTA), coronary artery calcium (CAC) scoring, echocardiography, and biomarkers.
- Analysis of multidisciplinary management approaches, including risk factor modification, pharmacotherapies, and revascularization.
- Evaluation of newer treatments (colchicine, ivabradine, ranolazine, melatonin), cardiac rehabilitation, implantable defibrillators (ICD), and extracorporeal shockwave-revascularization.
Main Results:
- Stress-echocardiography defines CCS phenotypes.
- CAC scoring and CCTA are key for assessing atherosclerosis burden and functional significance.
- Multidisciplinary CCS management involves risk factor control, anti-inflammatory/anti-ischemic/antithrombotic therapies, and revascularization.
- Emerging therapies and cardiac rehabilitation improve outcomes and quality of life.
Conclusions:
- Effective CCS management requires a multidisciplinary approach integrating advanced diagnostics and tailored therapies.
- Newer pharmacological agents and lifestyle interventions like cardiac rehabilitation are vital for improving patient prognosis and quality of life.
- Advanced treatments offer options for refractory CCS symptoms and sudden cardiac death prevention.
Introduction:
Chronic coronary syndrome (CCS) remains the leading cause of death worldwide with high admission/re-admission rates. Medical databases were searched on CCS & its management.
Areas Covered:
This review discusses phenotypes per stress-echocardiography, noninvasive/invasive testing (coronary computed-tomography angiography-CCTA; coronary artery calcium - CAC score; echocardiography assessing wall-motion, LV function, valvular disease; biomarkers), multidisciplinary management (risk factors/anti-inflammatory/anti-ischemic/antithrombotic therapies and revascularization), newer treatments (colchicine/ivabradine/ranolazine/melatonin), cardiac rehabilitation/exercise improving physical activity and quality-of-life, use of the implantable-defibrillator, and treatment with extracorporeal shockwave-revascularization for refractory symptoms.
Expert Opinion:
CCS is age-dependent, leading cause of death worldwide with high hospitalization rates. Stress-echocardiography defines phenotypes and guides prophylaxis and management. CAC is a surrogate for atherosclerosis burden, best for patients of intermediate/borderline risk. Higher CAC-scores indicate more severe coronary abnormalities. CCTA is preferred for noninvasive detection of CAC and atherosclerosis burden, determining stenosis' functional significance, and guiding management. Combining CAC score with CCTA improves diagnostic yield and assists prognosis. Echocardiography assesses LV wall-motion and function and valvular disease. Biomarkers guide diagnosis/prognosis. CCS management is multidisciplinary: risk-factor management, anti-inflammatory/anti-ischemic/antithrombotic therapies, and revascularization. Newer therapies comprise colchicine, ivabradine, ranolazine, melatonin, glucagon-like peptide-1-receptor antagonists. Cardiac rehabilitation/exercise improves physical activity and quality-of-life. An ICD protects from sudden death. Extracorporeal shockwave-revascularization treats refractory symptoms.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Pancreatitis II: Collaborative Care
Assessment:
COPD: Management Using Bronchodilators and Corticosteroids
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Chronic Obstructive Pulmonary Disease-I: Introduction

